Baseline characteristics of the study population (N = 1760) by intervention group, Iquitos, Loreto, Peru (September 2011-July 2013).

*1Group 1 (MBD/PBO) = mebendazole at the 12-month visit and placebo at the 18-month visit2Group 2 (PBO/MBD) = placebo at the 12-month visit and mebendazole at the 18-month visit3Group 3 (MBD/MBD) = mebendazole at the 12 and 18-month visit4Group 4 (PBO/PBO) = placebo at the 12 and 18-month visit**SD = standard deviation***Up-to-date vaccinations include those scheduled between birth and 11 months of age (i.e. one dose of Bacille Calmette-Guérin (BCG), one dose of hepatitis B, three doses of polio, three doses of pentavalent, two doses of rotavirus, and two doses of pneumococcal)Baseline characteristics of the study population (N = 1760) by intervention group, Iquitos, Loreto, Peru (September 2011-July 2013).